Beckman's Acquisition of Olympus Dx Business Clears FTC | GenomeWeb

NEW YORK (GenomeWeb News) – Beckman Coulter today said that its pending $780 million acquisition of the diagnostics business of Olympus has cleared US antitrust review by the Federal Trade Commission.

The firm said that it expects to close the deal in the third quarter of 2009, subject to certain additional conditions including approval from governments outside of the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.